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Chronic renal failure patients receiving haemodialysis (HD) exhibit a high incidence of 
cardiovascular disease and cancers. This is reported to be attributed to elevated levels of genetic 
damage coupled with lower levels of antioxidants, both endogenous and exogenous, and thus higher 
levels of oxidative stress. In the UK, HD patients are not prescribed supplementation, unlike other 
countries. This study is a blinded randomised intervention where 38 HD patients were assigned 
either placebo or novel supplement for 3 months. The modified comet assay was used to measure 
levels of DNA damage. The % of tail DNA damage was used to measure basal genetic damage; 
oxidative-specific DNA damage was measured with the addition of the enzymes Endo III and FPG. 
The HD patients receiving treatment had significantly reduced levels of all types of DNA damage 
compared to the placebo at 3 months. We observed a positive correlation between the duration on 
dialysis (months) and levels of Endo III -specific damage (p=0.041). Finally, in the HD placebo 
group, DNA damage levels were significantly increased from baseline at 3 months. This 
supplement, which is not available in the UK, may offer a treatment to reduce DNA damage, 
thereby helping to reduce the impact of HD on genomic damage and thus, cancers and CVD. As 
such, it warrants further investigation.  
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Chronic renal failure (CRF) has been described by [1] as a 
multifactorial immuno-inflammatory syndrome; this condition 
worsens as patient’s progress to maintenance dialysis therapy one 
treatment for CRF is haemodialysis (HD), however, the 
interaction between the HD patient’s blood and the 
semipermeable membranes contained in the haemodialysis 
apparatus increases levels of oxidative stress in these patients [2]. 
Indeed, during this interaction, circulating neutrophils are 
responsible for generating reactive oxygen species (ROS), such as 
superoxide, which further enhances levels of oxidative stress [3]. 
In addition to the damage from the dialysis membrane, HD 
patients recruit inflammatory cells, including neutrophils and 
macrophages, to the damaged parts of the kidney. Their oxidant-
generating enzymes, such as nitric oxide and NADPH oxidase, 
produce high concentrations of ROS and reactive nitrogen species 
(RNS) [4.] Excessive, long-lasting levels of ROS leads to 
metabolic dysregulation and /or the oxidation of end products 
including proteins, lipids, and DNA and/or oxidative damage in 
cells, tissues or organs [5,6]  The resulting proliferation of 
oxidative stress leads to an increase in DNA damage in patients 
undergoing HD [7] We have also reported that HD patients have 
increased levels of oxidative DNA damage compared to healthy 
individuals [8]  
Several studies have reported an increased risk of developing 
cancer in patients with CKD than in the general population 
[9,10,11] and in a retrospective cohort study, by Lee et al, [12], 
who reported an increased risk of hepatocellular, kidney, bladder, 
extra kidney/bladder urinary tract, and thyroid cancers in dialysis 
patients. In addition, Schupp et al., [13] suggest that end-stage 
renal disease (ESRD) patients have an increased risk of 
developing cancer as a result of a prolonged uremic state, chronic 
infection, lowered immune system, nutritional insufficiencies and 
altered DNA repair. 
HD patients are required to follow a restricted diet, which may 
lead to malnutrition in between 40-50% of these patients [14]. An 
impaired antioxidant system has been reported in HD patients 
with particular focus on serum selenium, vitamins C and E levels 
and activities of glutathione peroxide, catalase and superoxide 
dismutase, all have been reported to be lower than control 
participants [15-18]. These factors, acting alone or in 
Citation: Hannon-Fletcher M, Moffitt TA and Garrett PJ (2021). Oxidative DNA Damage Is Reduced Following a Novel 3-Month 
Supplementation Intervention in Hemodialysis Patients. J Biomed Sci Res 3(2): 145         DOI: https://doi.org/10.36266/JBSR/145   
  
Pubtexto Publishers | www.pubtexto.com                                           2                                                                                    J Biomed Sci Res 
combination, further compromise these patients and may lead to 
the elevated levels of ROS and increased level of cancers in this 
patient group.  
The European Standards Committee on Oxidative Damage (19) 
recommended that the comet assay was the most accurate method 
for measuring DNA damage within eukaryotic cells. This is a 
sensitive, single gel electrophoresis technique for detecting DNA 
strand breaks at the level of individual cells. Furthermore, the 
comet assay has various modifications to detect specific base 
alterations [20]. One such modified assay uses the bacterial 
enzymes to identify oxidative specific damage; endonuclease III 
(Endo III) and Formamidopyrimidine DNA Glycosylase (FPG) 
which identify pyrimidine- pyrimidine breaks and purine-purine 
breaks respectively [21]. This therefore enables the comparison of 
oxidative specific damage at baseline and post study.  
Given the impaired antioxidant status in HD patients outlined 
above, supplementation with antioxidants has been suggested as a 
treatment to reduce cardiovascular mortality and morbidity in 
CKD patients however, in a Cochrane Review [22] the authors 
reported no clear overall effect on cardiovascular mortality 
however, supplementation in pre-dialysis CKD patients may 
prevent progression to ESKD. 
Supplementation with Vitamin E has been reported by several 
authors [23-26] to be beneficial and they report a reduction in 
PUFA peroxidation. In addition, clinical trial results have also 
shown positive results with Vitamin E supplementation in HD 
patients [27].  
Supplementation with Vitamin C, Vitamin E and catalase have 
been reported to show small reductions or no effect on oxygen 
radical generated DNA Damage using the comet assay [28]. 
Given these data we conclude that the benefits of using a single 
antioxidant supplementation regime in HD patients, still remain 
controversial. This may be due the abnormalities do not seem to 
respond readily to single intervention strategies such as folic acid, 
Vitamin C, or antioxidant treatment alone [29-31]. 
Therefore, we have designed a micronutrient supplement of 
physiological doses of trace elements and antioxidant vitamins to 
investigate whether replenishment of these could counteract the 
actions of ROS and therefore decrease the levels of oxidative 
DNA damage in HD patients. 
Materials and Methods 
Participants  
Thirty-eight individuals undergoing HD at the Western Health 
and Social Care Trust (WHSCT) were recruited to the study 
following informed consent. Ethical approval was obtained from 
the Office of Research Ethics Committees, Northern Ireland 
(ORECNI) and Research Governance approval from WHSCT. All 
procedures followed were in accordance with the ethical 
standards of the committee on human experimentation 
(institutional and national) and with the Helsinki Declaration of 
1975, as revised in 2000. Exclusion criteria included individuals 
who were smokers, had known alcohol abuse in the preceding 12 
months, severe liver disease, severe uncontrolled cardiac or 
respiratory disorder, pre-exciting malignancy, pregnancy or breast 
feeding and already recruited to other clinical trials. Any 
volunteers who had taken vitamin supplements prior to baseline, 
had a four week wash out period before the study started. Once 
participants had provided informed consent they were enrolled 
onto the study. Each participant was given a unique study 
identifier on enrolment, all data was treated in a confidential 
manner, with hard copies stored in a locked filing cabinet at 
Ulster University and electronic data protected by a unique 
password.  
Routine Blood Sampling 
As part of the routine clinical management of HD, all patients 
provide monthly blood samples; while the routine sample was 
being collected an additional 8ml blood, was collected into 
lithium-heparin coated vacuettes for analysis of DNA damage.  
Comet Assay 
The protocol used was first described by Singh et al. [32]. and 
included the modifications described by Collins et al. [33]. In 
summary, approximately 100,000 cells were mixed well with 
75µl of 0.5% low melting point agarose. This mixture was then 
pipetted onto the slides pre-prepared with normal melting point 
agarose gels. For each blood sample, a total of four gels were 
prepared. These slides were left to solidify in a fridge (4⁰C) for at 
least 15 minutes. Fresh lysing solution was prepared (using 1% 
Triton-X, 10nM Tris, 10mM Na2-EDTA and 2.5M NaCl.) The 
slides were left in lysis solution overnight, in a container which 
blocks out light. Slides were then washed three times in calcium 
and magnesium free PBS, for five minutes each time. After this, 
the gels were treated with 20µl of either FPG, Endo III Buffer, or 
Endo III enzyme. One slide was left untreated, to be used as a 
blank. These were left for 45minutes at 4⁰C before being 
horizontally placed in an electrophoresis chamber, and submerged 
in freshly prepared electrophoresis buffer (1mM EDTA & 
300mM NaOH at pH 13). Slides were left in this buffer for 20 
minutes to allow for unwinding of the DNA with exposure of 
alkali-labile sites. Electrophoresis was then carried out at 25V and 
300mA for 20 minutes. After this, the slides were removed from 
the electrophoresis chamber and washed in neutralising solution 
(0.4M Tris, pH 7.5) three times for five minutes each. Each gel 
was then stained with 20µl of ethidium bromide (20µl/ml) and 
coverslips placed on the slides before analysis under the 
fluorescence microscope.  
Throughout this study, % DNA in the comet tail was used as the 
parameter to determine levels of DNA damage, i.e. the % of total 
nuclear DNA that migrated to the tail. Fifty comets per gel were 
analysed, and the mean percentage of DNA in the tail was used to 
indicate the frequency of DNA breaks. The % tail DNA in 
untreated cells (buffer only) can be subtracted from the % DNA 
in the tails of cells with enzyme (FPD/ENDO III enzyme) to give 
the net amount of damage represented by each of these enzymes. 
This has been reported as the net oxidative-specific DNA damage. 
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Image Analysis of Cells 
Within one hour of staining with ethidium bromide, the cells were 
observed using a Nikon Optiphot compound microscope fitted 
with a Nikon Fluor objective of 0.85 of numerical aperture and an 
epifluorescence mercury lamp. The Komet 5.5 Image Analysis 
System was used, and the cells were viewed at a magnification of 
x 40. Fifty randomly chosen cells were analysed per slide, and 
results were given as % tail DNA for the levels of DNA damage. 
Intervention  
This was a double blinded study where participants were 
randomised, on the basis of their baseline homocysteine (tHcy) 
level, to receive either micronutrient supplement or placebo for 3 
months. Supplements were prepared by the Pharmacist in 
WHSCT and administered weekly to the participants. And used 
boxes collected, records were kept of un-used pills and 
participants were only included in the analysis if they had taken 
90% of the supplement. The micronutrient supplement contained: 
Folic acid, 800µg; Vitamin B6, (10mg); Vitamin B12, (12µg); 
Thiamin, (B1) 1mg; Riboflavin (B2), 1.6mg; Pantathenic acid 
(B5), 1mg; Vitamin C, 60mg; Vitamin E ,10mg; Vitamin K, 
65µg; Zinc, 15mg; Copper,1.5mg; and Selenium, 75µg 
(Biosynergy, London, UK). Placebo contained:  
Statistical Analysis 
This was carried out using version 26.0 of the Statistical Packages 
for Social Sciences (SPSS) and Microsoft Excel. Data are 
expressed as mean ± standard error. A paired Student t-test was 
employed to compare differences between treatment vs treatment 
and placebo vs placed at baseline and post treatment; while and 
unpaired t-test was used to compare placebo and treatment post 
treatment. Pearson’s product-moment coefficient was used to 
assess any correlation between levels of DNA damage post 
treatment and age, gender, BMI, duration of dialysis and diabetes. 
A P-value <0.05 was set to be statistically significant.  
Results 
Baseline characteristics of all participants in the two experimental 
groups are presented in Table1. No significant differences were 
observed at baseline between placebo and treatment groups. 
Thirty-eight haemodialysis patients enrolled but only 30 
completed the study. Reasons for withdrawal included: enrolment 
on another study, receiving a transplant and several participants 
passed away during the study.  
Table 1: Baseline Participants Characteristics. 
Characteristic Placebo group Treatment group 
 
(n-19) (n=18) 
Age (Years) 62.85 ± 10.95 64.89 ± 8.29 
Male/Female (n/n) 7-Dec 8-Oct 
Diabetes (n (%)) 6 (31.6%) 7 (38.9%) 
Dialysis Duration (months) 27.00 ± 17.75 27.33 ± 38.09 
BMI (kg/m2) 27.08 ± 6.43 26.29 ± 4.80 
BMI: Body Mass Index; Values are presented as mean ± Standard 
deviation. 
The comet assay was used to measure general DNA damage i.e., 
Alkaline damage no enzymes and levels of oxidative DNA 
damage in placebo and treatment groups at baseline and post- 
intervention. FPG and Endo III net specific oxidative DNA 
damage, was calculated by subtracting the buffer only DNA 
damage levels from the FPG and Endo III damage levels.  
We observed a significant reduction in DNA damage (all types) in 
the treatment group post intervention, compared to baseline 
(Figure 1). While in the placebo group DNA damage was 
significant higher at post intervention (**p>0.00; *p>0.05) 
compared to baseline in all DNA damage types (Table 2). 
Net Oxidative specific DNA damage, FPG and Endo III was 
significantly reduced in the treatment group, (* p>0.05; 
**p>0.001, respectively) post intervention compared to baseline 
(Figure 1), while in the placebo group FPG was significantly 
higher (p>0.05) post intervention and Endo III was lower but did 
not reach significance.  
In addition, we observed a positive correlation between the 
duration on dialysis (months) and levels of Endo III specific 
damage (p=0.041). 
 
Figure 1: DNA Damage in Treatment Group Pre- and Post-Intervention. 
Values are mean ± SD ***p>0.001  
Table 2: DNA Damage in Placebo Group Post-Intervention. 
% Tail 
DNA 
Alkaline FPG ENDO III 
Baseline 22.22 ± 8.96 23.24 ± 9.02 22.37 ± 10.28 
3 Months 37.27* ± 8.11 30.44** ± 9.77 35.26*** ± 9.32 
Values are mean ±SD ***p>0.001; **p>0.01* p>0.05. 










Baseline 5.92 ± 5.46 5.87± 5.68 
3 Months 6.88* ± 8.21 2.0 ± 6.41 
Treatment 
Baseline 6.85±6.81 6.76±5.76 
3 Months 1.55*±3.11 0.37**±2.15 
Values are mean ±SD **p>0.001; * p>0.05. 
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Discussion 
This study sought to investigate the effect of a novel 
supplementation on levels of DNA damage in HD patients. In the 
UK HD patients are not routinely provided with supplements, 
only 3.7% of HD patients in the UK receive any supplementation, 
unlike other countries, the Dialysis Outcomes and Practice 
Patterns Study [34] reported a large variation by region in the 
percentage of patients administered with water-soluble vitamins, 
ranging from 3.7% in the United Kingdom, 5.6% in Japan, 37.9% 
in Spain, to a high of 71.9% in the United States. Yet the use of 
water-soluble vitamins was associated with a substantially and 
significantly lower risk for mortality (RR, 0.84; P = 0.001) [34]. 
The supplement designed for this study included water- soluble 
vitamins, and co-factors for endogenous antioxidant enzymes 
(Superoxide dismutase and Glutathione peroxidase) and essential 
trace elements such as copper, zinc and selenium because of 
inadequate intake or excess removal by dialysis [34]. 
In the current study we observed a significant reduction in 
Alkaline, EndoIII, FPG and net oxidative specific FPG and 
EndoIII DNA damage post- intervention in the HD treatment 
group, while the placebo group had DNA damage levels 
significantly increased from baseline at 3 months, indicating the 
damaging high levels of oxidative stress were continuing in the 
untreated group. 
While the alkaline comet assay can be used to determine the 
levels of alkaline DNA damage present within leukocytes, the 
modified comet assay is a much more sensitive technique which 
specifically measures oxidative DNA damage. This is particularly 
important because it is specifically oxidative DNA damage which 
has been strongly linked to the development of cancer [35].  
The modified assay can measure oxidative DNA damage by 
including lesion specific enzymes such as End III and FPG since 
the DNA is readily digested. FPG recognises the common 
oxidised purine - 7, 8-dihydro-8-oxoguanine and ring opened 
purines; Endo III converts oxidised pyrimidines to strand breaks 
[35]. The results of previous investigations in this lab, showed 
that levels of alkaline DNA damage and oxidative-specific Endo 
III DNA damage were significantly increased among HD patients, 
compared to control participants (9). In addition, Stoyanova et al. 
[36] assessed a population of 253 patients with chronic kidney 
disease, including 77 receiving HD. HD patients had higher levels 
of DNA damage than those not currently on HD. The study also 
defined a positive correlation between DNA damage and 
creatinine and protein levels in plasma. Quoting reference data 
from Muller et al. [37] the authors concluded that their findings 
represented a significant increase in oxidative DNA damage. Our 
results are in agreement with these studies and also in accordance 
with a study by Stopper et al [38] who showed a significant 
increase of oxidative DNA damage in individuals undergoing HD 
treatment. 
Here we show that the damaging effects of the elevated levels of 
oxidative stress can be ameliorated by this novel supplement. This 
is important given the restrictive diet HD patients need to 
maintain resulting in decreased level of antioxidants are 
consumed (14). All these factors contribute to decreased levels of 
antioxidants available to repair the damage caused by increased 
levels of ROS. 
In addition, we observed, in agreement with Stoyanova et al. [36], 
a positive correlation between the duration on dialysis (months) 
and levels of Endo III specific damage (p=0.041). This suggests a 
cumulative negative effect of increased levels of oxidative stress 
on Endo III DNA disruption, which may contribute to the 
increased cancer risk observed in this patient group. Such results 
reinforce the findings from this investigation and this effect is 
worthy of additional research as it may contribute in part, to the 
increased incidences of cancer and CVD within patients receiving 
HD treatment.  
Finally, treatment with this novel supplement significantly 
reduced all DNA damage in the HD treatment group. This 
provides some evidential support for the supplementation of HD 
patients in the UK, in an attempt to reduce the levels of damaging 
oxidative stress. In addition, the placebo group continued to show 
a significant increase in all levels of DNA damage from baseline 
and compared to the treatment group. 
We propose that these results provide a positive treatment 
regimen for HD patients. The treatment is low in cost and may 
protect the patients from the damaging effects of high levels of 
oxidative stress and the resulting DNA damage, and thus 
potentially reduce the mortality. However, we acknowledge this 
was a small group and further research is required to confirm 
these positive findings. 
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